GMAB

Genmab AS (GMAB)

Genmab AS

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:GMAB

1 2 3 4 5 6 7 8 9 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/06/01	23:00	Business Wire	Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)	NASDAQ:GMAB	Genmab AS
2024/05/29	00:29	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS
2024/05/24	06:00	Business Wire	Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting	NASDAQ:GMAB	Genmab AS
2024/05/22	00:38	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS
2024/05/22	00:18	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS
2024/05/22	00:10	Business Wire	Genmab Completes Acquisition of ProfoundBio	NASDAQ:GMAB	Genmab AS
2024/05/14	23:05	Business Wire	Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress	NASDAQ:GMAB	Genmab AS
2024/05/14	00:29	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS
2024/04/30	07:40	Business Wire	TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer	NASDAQ:GMAB	Genmab AS
2024/04/30	07:40	Business Wire	FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer	NASDAQ:GMAB	Genmab AS
2024/04/03	14:35	Business Wire	Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio	NASDAQ:GMAB	Genmab AS
2024/03/12	02:43	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS
2024/03/05	03:50	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS
2024/03/05	03:26	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS
2024/03/02	07:04	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:GMAB	Genmab AS
2024/03/01	01:47	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS
2024/02/29	01:06	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS
2024/02/28	06:55	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS
2024/02/27	21:45	Business Wire	U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma	NASDAQ:GMAB	Genmab AS
2024/02/27	02:19	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS
2024/02/27	00:40	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS
2024/02/23	06:28	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:GMAB	Genmab AS
2024/02/21	01:30	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS
2024/02/15	05:42	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS
2024/02/15	03:49	Edgar (US Regulatory)	Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]	NASDAQ:GMAB	Genmab AS
2024/02/15	02:30	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS
2024/02/02	20:45	Business Wire	Tisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical Cancer	NASDAQ:GMAB	Genmab AS
2024/02/01	01:17	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS
2024/01/23	23:04	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS
2024/01/09	21:45	Dow Jones News	Pfizer, Genmab Get Speedy FDA Review of Tivdak Full Approval	NASDAQ:GMAB	Genmab AS